MyHC-beta: A Potential Drug Target for Cardiovascular Diseases

Target Name: MYH7

NCBI ID: G4625

MYH7

MyHC-beta: A Potential Drug Target for Cardiovascular Diseases

MyHC-beta, also known asMYH7, is a protein that is expressed in various tissues throughout the body. It is a key regulator of the myocardial contractile function and has been identified as a potential drug target for various cardiovascular diseases, including heart failure, hypertension, and atrial fibrillation.

MyHC-beta is a member of the myosin heavy chain (MYH) family, which is a group of proteins that are responsible for the mechanical properties of muscle cells. The MYH family plays a crucial role in the regulation of muscle contraction and relaxation, and is thought to be involved in the development and maintenance of various cardiovascular diseases.

One of the key functions of MyHC-beta is its role in regulating the contractile force of myocardial cells. This is important for maintaining normal heart rhythm and for ensuring that the heart is able to pump enough blood to meet the body's needs. MyHC-beta is known to play a key role in the regulation of the contractile force by affecting the amount of calcium ions that enter the cells during muscle contraction.

In addition to its role in regulating muscle contraction, MyHC-beta is also involved in the regulation of cell signaling pathways that are important for the development and maintenance of cardiovascular disease. For example, MyHC-beta has been shown to play a role in the regulation of the angiogenesis (the formation of new blood vessels), and has been shown to be involved in the development of various cardiovascular diseases, including heart failure and hypertension.

Due to its involvement in the regulation of muscle contraction and cell signaling pathways, MyHC-beta has been identified as a potential drug target for a variety of cardiovascular diseases. Studies have shown that inhibiting the activity of MyHC-beta has the potential to improve heart function and reduce the risk of cardiovascular disease.

In addition to its potential as a drug target, MyHC-beta is also a potential biomarker for the diagnosis and assessment of cardiovascular disease. For example, studies have shown that the level of MyHC-beta is often decreased in individuals with heart failure, and that this can be used as a diagnostic marker for this condition. Similarly, the level of MyHC-beta has been shown to be elevated in individuals with hypertension, and this can be used as a diagnostic marker for this condition.

Overall, MyHC-beta is a protein that is involved in the regulation of various physiological processes that are important for the development and maintenance of cardiovascular disease. As a potential drug target and biomarker, MyHC-beta is a promising target for the development of new treatments for a variety of cardiovascular diseases. Further research is needed to fully understand the role of MyHC-beta in the development and maintenance of cardiovascular disease, and to determine the most effective way to use this protein as a drug or biomarker.

Protein Name: Myosin Heavy Chain 7

Functions: Myosins are actin-based motor molecules with ATPase activity essential for muscle contraction. Forms regular bipolar thick filaments that, together with actin thin filaments, constitute the fundamental contractile unit of skeletal and cardiac muscle

The "MYH7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MYH7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets